RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwire - January 17, 2008) - Adherex Technologies Inc. (TSX: AHX)(AMEX: ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that it has completed patient enrollment in the Phase I portion of the clinical trial of systemic ADH-1 in combination with isolated limb infusion melphalan and is proceeding with a multi-institutional Phase IIb expansion of the study.
